Consider an illustrative founder seeking an eight-figure Series A. The presentation is polished, but the evidence behind the plan needs a closer look. This is a teaching scenario, not an account of a verified client engagement.
Cost curves bending the right way. I asked her three questions.
Contracted revenue: zero.
Signed buyers: none, three non-binding letters of intent, all conditional on a regulatory approval she had not filed for.
Monthly burn: six figures, against nine scientists in a glass-walled lab.
The company has raised a legitimate question about its next stage. The round label alone does not establish customer demand, process readiness or the funding needed to reach the next milestone.
The scenario is a prompt for review, not evidence that a typical founder is in this position.
This article examines a practical distinction: the funding stage named in a cap table and the commercial evidence available to support the next commitment.
Use the five questions below to identify the next piece of evidence your operating plan needs.
Today’s problem is the one that arrives twice.
The assumption to test
The myth is your stage is the round you raised. You closed a seed, so you are a seed company. You closed a Series A, so you are a Series A company. The cap table is treated as the diagnosis.
A round label describes financing, while customer, process and operating evidence describe what the company can currently support. A research-intensive business can legitimately remain pre-revenue. Its capital plan should make the next development milestone and dependencies explicit.
Investors underwrite this too. They want the multi-molecule platform exit, so they fund the narrative and call the gap execution risk. It is a mutual cosplay. Founders pretend to run a platform, investors pretend to fund a category leader, and the bill arrives on schedule.
What this costs you, and the one move that fixes it today
The damage is not abstract. It is hiring a VP of Sustainability before you have a repeatable, positive-margin transaction. It is leasing custom bioreactors before downstream recovery yields hold at pilot scale. It is burning the seed running a Series A organisation chart, which is the fastest way to make the actual Series A unraisable.
Ask what buyers have actually committed: a paid contract, a conditional agreement, a non-binding letter of intent or informal interest. Each provides different evidence. An LOI can be useful, but its terms and conditions must be visible in the pipeline and cash plan.
A funding round and a commercial milestone answer different questions. Review both before making hiring, infrastructure or fundraising commitments.
One-minute brief
This is an editorial diagnostic rather than an objective or validated scoring function. Customer evidence, economics, capital needs, growth and exit planning can develop together; they do not form a universal sequence for every business.
The five areas below give founders and investors a shared way to inspect the plan. The worked comparison is illustrative and does not describe verified client outcomes.
The diagnostic is uncomfortable on purpose. Used early, it is free. Used by an investor in diligence, it is the end of the conversation.
The five gates
The five areas are a review framework: customer evidence, unit economics, capital efficiency, defensible growth and exit assumptions. Their order and importance depend on the business.
Gate 1. Validation
Validation means evidence that a defined customer has a reason to buy and, where relevant, buy again. A repeat-purchase threshold depends on category, purchase cycle, channel and study design. Forty percent is not a universal product-market-fit test.
Gate 2. Unit economics.
Check contribution margin, acquisition cost and expected customer value using the actual business model. A three-to-one LTV/CAC ratio is a possible planning benchmark, not a food biotech standard or proof that fixed costs can be covered.
Gate 3. Capital efficiency
Make financing dependencies visible. Cash conversion, burn and the next milestone need a model appropriate to the company. Fixed targets such as forty-five-day cash conversion or a burn multiple below two are not universal gates for capital-intensive R&D businesses.
Gate 4. Defensible growth
Examine what makes growth defensible: performance, know-how, customer relationships, supply, IP and regulatory position. Regulatory permission may matter, but it does not automatically create the strongest competitive advantage.
Gate 5. Exit positioning
You have built what an acquirer actually buys, not what a pitch audience applauds. These are not the same object.
The honest stage is the lowest gate you have genuinely cleared. Not the highest one you can describe.
The same question, at your stage
Pre-seed. Are you a company or an academic project?
Define the next experiment, its budget and the result that would change the plan. Any litre, time or spending threshold must come from the project requirements, rather than a universal stop rule.
Seed. Are you a B2B venture or a lab with a logo?
Check what a proposed co-development arrangement commits each party to fund, test and decide. A paid agreement and a non-binding expression of interest provide different evidence; neither alone assigns a company a universal funding stage.
Series A. Are you a scaleup or a seed-extension in makeup?
The number that matters is contracted revenue with a repeat margin, not pipeline and not an unhedged manufacturing model. Investors: ask what fraction of the plan assumes infrastructure that should have been rented.
Growth. Are you a company or a venture-backed line item?
Stress-test the operating plan using plausible staffing and demand scenarios. Do not treat a fixed thirty-percent headcount cut as a diagnostic of whether a company is real.
Related analysis: Why most Food Biotech platforms should start as ingredient companies
Illustrative worked example
The following comparison is hypothetical. Two teams begin with similar technology and capital, then choose different operating priorities.
The first spent year one building the company. A brand agency. An internal chief operating officer. A premium office. Two hundred thousand euros on identity and packaging renders. By the second year the consumer story had excited investors and nothing else, and he was raising a bridge at a punishing down-round, then another, on the assumption the next round would come.
The second spent year one inside a contract manufacturer’s plant in northern Germany, running unglamorous free toll-runs to learn the exact heat-and-shear rejection criteria that commercial buyers will not put on paper. No brand. No office. By the second year three industrial buyers were co-funding her scale-up trials against pre-orders, because she had something they had already agreed to pay for.
In this hypothetical comparison, the second team revises its scope and spending around a paid contract. Whether that reaches profitability depends on the numbers. The example illustrates an operating choice, not a verified commercial outcome.
It was which stage each founder decided to actually operate at, before the market forced the decision for them.
The diagnostic question
Use this question in your next project review, or add a source in the article discussion.
Use this question in your next project review, or add a source in the article discussion.
Sources and scope
This is an edited adaptation of the author’s full Substack essay, first published 2026-05-19. Examples and editorial frameworks are distinguished from measured evidence. Source checks and editing: 16 October 2026.
Read the original Substack version. Read the FoodEdge editorial standards or suggest a correction.
Cover photograph: Photo by Trnava University / Unsplash. Context image, not a photograph of a company or experiment discussed here. Photo licence.
